1000th Patient implanted with Symetis‘ ACURATE TA31.10.2013 09:08
Symetis Inc., a privately‐owned Swiss company focused on transcatheter aortic valve implantation (TAVI) systems announced today that it has achieved a symbolic milestone: the implantation of the 1000th ACURATE TA transaortic valve.
The first ACURATE TA valve was implanted in November 2009 at the Leipzig Herzzentrum by Pr. T. Walther and Dr. J. Kempfert. ACURATE TA was granted CE mark in September 2011 and the first commercial implant was performed in November 2011. In April 2012, Symetis reported the clinical outcome of its SAVI Registry (n=250) showing superior results in the patient population treated in everyday clinical settings: more than 97% of patients with no relevant paravalvular leak, procedural success rate 98% and stroke rate below 2%.
During the recent EACTS 2013 in Vienna (Austria), the versatility of the ACURATE TA system was further demonstrated by Pr. Michael Hilker (Universitatsklinikum Regensburg) as an effective solution to failed biological valves and by Dr. Wendt (Universitatsklinikum Essen) as a safe and effective treatment for aortic insufficiency.
Since its first use, ACURATE TA has been implanted to date in over 1000 patients in Europe, Argentina and Japan. To further support its transapical franchise, Symetis will soon initiate two new studies.
“I want to express the company’ gratitude to all those physicians who trusted our company and our team, and helped us achieve this milestone, which definitively sets Symetis among the established TAVI players,” said Jacques R. Essinger, CEO of Symetis. “
PD Dr. H. Treede (Universitares Herzzentrum Hamburg ), who was among the ACURATE TA first‐in‐man study investigators, added: “I remember my comment after the first two cases: easy. In the meantime, the ACURATE TA system has proven itself by producing superior and reliable clinical outcomes.”
“We believe that the key to TAVI success is a combination of ease of use and clinical performance. Thanks to the Symetis R&D team and the essential input from our early users, we have achieved this winning combination. We are however committed to further perfect our results”, said Jacques R. Essinger. ”To have treated 1000 patients in little more than two years in a highly competitive environment is confirmation of our strong company quality. This milestone sets us on the path towards further powerful growth.”